The study marks UC Berkeley’s first experiments on humans with a Schedule I substance — those which the federal government considers to have no currently accepted medical use.
Privacy concerns and accuracy issues causing false positives and false negatives remain, but they do not outweigh the benefits, says this San Jose State data scientist.